BRPI0717697A2 - composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos - Google Patents

composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos

Info

Publication number: BRPI0717697A2
Authority: BR; Brazil
Prior art keywords: compound; disease; treating; products; combination
Prior art date: 2006-12-22

Application number

BRPI0717697A

Other languages

English (en)

Inventor

Eloisa Navarro Romero

Julio Cesar Castro Palomino Laria

Maria Estrella Lozoya Toribio

Montserrat Erra Sola

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-22

Filing date

2007-12-21

Publication date

2016-03-22

2007-04-23 Priority claimed from ES200701086A external-priority patent/ES2327372B1/es

2007-12-21 Application filed by Almirall Lab filed Critical Almirall Lab

2016-03-22 Publication of BRPI0717697A2 publication Critical patent/BRPI0717697A2/pt

2022-05-03 Publication of BRPI0717697B1 publication Critical patent/BRPI0717697B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

BRPI0717697-0A 2006-12-22 2007-12-21 Composto, composição farmaceutica e combinação de produtos BRPI0717697B1 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
ES200603250A ES2319596B1 (es)	2006-12-22	2006-12-22	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ESP200603250		2006-12-22
ES200701086A ES2327372B1 (es)	2007-04-23	2007-04-23	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ESP200701086		2007-04-23
PCT/EP2007/011401 WO2008077639A1 (en)	2006-12-22	2007-12-21	Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors

Publications (2)

Publication Number	Publication Date
BRPI0717697A2 true BRPI0717697A2 (pt)	2016-03-22
BRPI0717697B1 BRPI0717697B1 (pt)	2022-05-03

Family

ID=39319647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717697-0A BRPI0717697B1 (pt)	2006-12-22	2007-12-21	Composto, composição farmaceutica e combinação de produtos

Country Status (31)

Country	Link
US (2)	US8258308B2 (pt)
EP (1)	EP2121614B1 (pt)
JP (1)	JP5318776B2 (pt)
KR (1)	KR101435233B1 (pt)
CN (1)	CN101589025B (pt)
AR (1)	AR064444A1 (pt)
AU (1)	AU2007338321B2 (pt)
BR (1)	BRPI0717697B1 (pt)
CA (1)	CA2674512C (pt)
CL (1)	CL2007003666A1 (pt)
CY (1)	CY1113687T1 (pt)
DK (1)	DK2121614T3 (pt)
EC (1)	ECSP099395A (pt)
ES (2)	ES2319596B1 (pt)
HR (1)	HRP20120697T1 (pt)
IL (1)	IL199188A (pt)
ME (1)	ME01475B (pt)
MX (1)	MX2009006408A (pt)
MY (1)	MY153393A (pt)
NO (1)	NO341991B1 (pt)
NZ (1)	NZ577017A (pt)
PE (1)	PE20081846A1 (pt)
PL (1)	PL2121614T3 (pt)
PT (1)	PT2121614E (pt)
RS (1)	RS52514B (pt)
RU (1)	RU2469024C2 (pt)
SI (1)	SI2121614T1 (pt)
TW (1)	TWI405572B (pt)
UY (1)	UY30794A1 (pt)
WO (1)	WO2008077639A1 (pt)
ZA (1)	ZA200903335B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
ES2327372B1 (es) *	2007-04-23	2010-08-24	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) *	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) *	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0921258A2 (pt) *	2008-11-07	2018-10-23	4Sc Ag	terapia combinatória compreendendo inibidor de dhodh e metotrexato para o tratamento de doença autoimune
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228367A1 (en)	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) *	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
TWI530286B (zh)	2009-05-04	2016-04-21	帕納特斯製藥格斯有限公司	作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) *	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP3646859A1 (en)	2009-11-27	2020-05-06	Boehringer Ingelheim International GmbH	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2338888A1 (en)	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en)	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en)	2010-05-06	2014-04-01	Rhizen Pharmaceuticals Sa	Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444088A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Amino derivatives for the treatment of proliferative skin disorders
EP2444086A1 (en)	2010-10-22	2012-04-25	Almirall, S.A.	Combinations comprising DHODH inhibitors and COX inhibitors
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2455080A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of crohn's disease
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012109329A2 (en)	2011-02-08	2012-08-16	Children's Medical Center Corporation	Methods for treatment of melanoma
US10016402B2 (en)	2011-02-08	2018-07-10	Children's Medical Center Corporation	Methods for treatment of melanoma
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en)	2011-11-21	2013-05-22	Almirall, S.A.	2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
PL2915804T3 (pl) *	2012-10-31	2019-09-30	Fujifilm Toyama Chemical Co., Ltd.	Nowe pochodne aminy lub ich sole jako inhibitory tnf alfa
UY35332A (es)	2013-02-15	2014-11-28	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
WO2015077535A2 (en)	2013-11-22	2015-05-28	Genzyme Corporation	Novel methods for treating neurodegenerative diseases
KR102265277B1 (ko)	2014-04-11	2021-06-16	판옵테스 파르마 게스.엠.베.하.	바이러스 억제 화합물로서의 항-염증제
CN106572968A (zh) *	2014-05-08	2017-04-19	帕诺泰斯制药有限公司	用于治疗眼科疾病和障碍的化合物
WO2016200778A1 (en) *	2015-06-08	2016-12-15	Children's Medical Center Corporation	Methods for treatment of melanoma
WO2016202800A1 (en)	2015-06-16	2016-12-22	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
WO2018136009A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
WO2018136010A1 (en)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Combination therapy
US11311548B2 (en)	2017-03-02	2022-04-26	Aslan Pharmaceuticals Pte. Ltd.	Cancer therapy
EP3589286B1 (en)	2017-03-02	2022-08-03	ASLAN Pharmaceuticals Pte Ltd	Dhodh inhibitor for treating haematological cancer
CN108530310B (zh) *	2017-03-02	2025-01-28	中国科学院上海药物研究所	2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP6978251B2 (ja) *	2017-03-03	2021-12-08	アスランファーマシューティカルズピーティーイーリミテッド	がん治療
WO2018222135A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
WO2018222134A1 (en)	2017-06-02	2018-12-06	Aslan Pharmaceuticals Pte Ltd	Cancer therapy
EP3761960B1 (en)	2018-03-09	2023-11-22	Kiora Pharmaceuticals GmbH	Ophthalmic formulation
JP7126556B2 (ja)	2018-09-28	2022-08-26	富士フイルム株式会社	シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
JP7409670B2 (ja) *	2018-12-21	2024-01-09	国立大学法人北海道大学	多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
EP3750892A1 (en)	2019-06-14	2020-12-16	Yerevan State University	Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
WO2021085582A1 (ja)	2019-10-31	2021-05-06	富士フイルム株式会社	ピラジン誘導体またはその塩およびその利用
JP7598380B2 (ja) *	2020-07-30	2024-12-11	富士フイルム株式会社	含窒素複素環化合物またはその塩、その利用、およびその中間体
WO2022081095A1 (en) *	2020-10-15	2022-04-21	Aslan Pharmaceuticals Pte. Ltd.	Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN116940359A (zh) *	2020-10-15	2023-10-24	亚狮康私人有限公司	用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
WO2023278778A1 (en) *	2021-06-30	2023-01-05	Ohio State Innovation Foundation	Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
US20230242558A1 (en) *	2022-01-31	2023-08-03	New Frontier Bio, Inc.	Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
US20250145570A1 (en) *	2022-02-03	2025-05-08	Aslan Pharmaceuticals Pte Ltd	Dhodh inhibitor polymorph
WO2025215126A1 (en)	2024-04-12	2025-10-16	Immunic Ag	Synthesis of vidofludimus and its calcium salt

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US529490A (en) *		1894-11-20		hegg-em
EP0040896B1 (en) *	1978-08-22	1984-04-25	Sumitomo Chemical Company, Limited	Synthesis of amides
JPH05331163A (ja) *	1991-03-26	1993-12-14	Kumiai Chem Ind Co Ltd	ピリジン誘導体及び除草剤
CN1047776C (zh) *	1993-10-01	1999-12-29	诺瓦蒂斯有限公司	具有药理学活性的吡啶类衍生物及其制备方法
CA2378713C (en)	1995-06-21	2003-08-12	Asta Medica Aktiengesellschaft	Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19547648A1 (de)	1995-12-20	1997-06-26	Hoechst Ag	Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de)	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en)	1998-02-27	1998-04-22	Univ Cardiff	Chemical compounds
HRP20020026A2 (en) *	1999-06-10	2003-08-31	Warner Lambert Co	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
ES2305287T3 (es)	2001-04-05	2008-11-01	Aventis Pharmaceuticals Inc.	Uso de (4'-trifluorometifenil)-amida del acido (z)-ciano-3-hidroxi-but-2-enoico para tratar la esclerosis multiple.
WO2002102374A1 (en) *	2001-06-19	2002-12-27	Merck & Co., Inc.	Amine salt of an integrin receptor antagonist
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003006424A1 (en) *	2001-07-10	2003-01-23	4Sc Ag	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
DE10202940A1 (de)	2002-01-24	2003-07-31	Sofotec Gmbh & Co Kg	Patrone für einen Pulverinhalator
US7258118B2 (en) *	2002-01-24	2007-08-21	Sofotec Gmbh & Co, Kg	Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es)	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
WO2004056746A1 (en)	2002-12-23	2004-07-08	4Sc Ag	Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) *	2002-12-23	2004-07-08	4Sc Ag	Dhodh-inhibitors and method for their identification
SE0400234D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New compounds, methods for their preparation and use thereof
MXPA06013435A (es)	2004-05-21	2007-03-23	Uab Research Foundation	Composiciones y metodos referentes a inhibidores de sintesis de pirimidina.
WO2006022442A1 (ja) *	2004-08-24	2006-03-02	Santen Pharmaceutical Co., Ltd.	ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CA2584655A1 (en)	2004-10-19	2006-04-27	Aventis Pharmaceuticals Inc.	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
MX2007004781A (es) *	2004-10-20	2007-05-11	Applied Research Systems	Derivados de 3-arilamino piridina.
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
CA2677457A1 (en)	2007-02-06	2008-08-14	Helen Tuvesson Andersson	New compounds, methods for their preparation and use thereof
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) *	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en)	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en)	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en)	2009-03-13	2010-09-22	Almirall, S.A.	Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en)	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

2006
- 2006-12-22 ES ES200603250A patent/ES2319596B1/es not_active Withdrawn - After Issue
2007
- 2007-12-13 UY UY30794A patent/UY30794A1/es active IP Right Grant
- 2007-12-17 CL CL200703666A patent/CL2007003666A1/es unknown
- 2007-12-17 TW TW096148215A patent/TWI405572B/zh active
- 2007-12-19 AR ARP070105721A patent/AR064444A1/es active IP Right Grant
- 2007-12-21 DK DK07866261.6T patent/DK2121614T3/da active
- 2007-12-21 AU AU2007338321A patent/AU2007338321B2/en active Active
- 2007-12-21 PL PL07866261T patent/PL2121614T3/pl unknown
- 2007-12-21 MY MYPI20092607A patent/MY153393A/en unknown
- 2007-12-21 KR KR1020097012714A patent/KR101435233B1/ko active Active
- 2007-12-21 ES ES07866261T patent/ES2389785T3/es active Active
- 2007-12-21 EP EP07866261A patent/EP2121614B1/en active Active
- 2007-12-21 HR HRP20120697TT patent/HRP20120697T1/hr unknown
- 2007-12-21 MX MX2009006408A patent/MX2009006408A/es active IP Right Grant
- 2007-12-21 RU RU2009127847/04A patent/RU2469024C2/ru active
- 2007-12-21 SI SI200731012T patent/SI2121614T1/sl unknown
- 2007-12-21 JP JP2009541921A patent/JP5318776B2/ja active Active
- 2007-12-21 RS RS20120388A patent/RS52514B/sr unknown
- 2007-12-21 NZ NZ577017A patent/NZ577017A/en unknown
- 2007-12-21 BR BRPI0717697-0A patent/BRPI0717697B1/pt active IP Right Grant
- 2007-12-21 WO PCT/EP2007/011401 patent/WO2008077639A1/en not_active Ceased
- 2007-12-21 US US12/520,237 patent/US8258308B2/en active Active
- 2007-12-21 PT PT07866261T patent/PT2121614E/pt unknown
- 2007-12-21 ME MEP-2012-104A patent/ME01475B/me unknown
- 2007-12-21 CA CA2674512A patent/CA2674512C/en active Active
- 2007-12-21 CN CN200780047756XA patent/CN101589025B/zh active Active
2008
- 2008-01-02 PE PE2008000062A patent/PE20081846A1/es active IP Right Grant
2009
- 2009-05-14 ZA ZA200903333A patent/ZA200903335B/xx unknown
- 2009-06-04 IL IL199188A patent/IL199188A/en active IP Right Grant
- 2009-06-09 EC EC2009009395A patent/ECSP099395A/es unknown
- 2009-06-22 NO NO20092380A patent/NO341991B1/no unknown
2012
- 2012-08-06 US US13/567,437 patent/US8691852B2/en active Active
- 2012-09-04 CY CY20121100791T patent/CY1113687T1/el unknown

Also Published As

Publication number	Publication date
KR20090090352A (ko)	2009-08-25
PL2121614T3 (pl)	2012-11-30
EP2121614A1 (en)	2009-11-25
NO20092380L (no)	2009-07-14
UY30794A1 (es)	2008-05-31
ECSP099395A (es)	2009-07-31
ES2319596B1 (es)	2010-02-08
US8258308B2 (en)	2012-09-04
MX2009006408A (es)	2009-06-23
ZA200903335B (en)	2010-06-30
CL2007003666A1 (es)	2008-07-04
CN101589025A (zh)	2009-11-25
RU2469024C2 (ru)	2012-12-10
ES2319596A1 (es)	2009-05-08
CA2674512A1 (en)	2008-07-03
JP5318776B2 (ja)	2013-10-16
RU2009127847A (ru)	2011-01-27
TWI405572B (zh)	2013-08-21
IL199188A (en)	2014-06-30
HRP20120697T1 (hr)	2012-09-30
US8691852B2 (en)	2014-04-08
WO2008077639A1 (en)	2008-07-03
SI2121614T1 (sl)	2012-10-30
HK1133014A1 (en)	2010-03-12
DK2121614T3 (da)	2012-09-17
TW200833332A (en)	2008-08-16
KR101435233B1 (ko)	2014-08-28
ES2389785T3 (es)	2012-10-31
US20100074898A1 (en)	2010-03-25
EP2121614B1 (en)	2012-06-20
AU2007338321A1 (en)	2008-07-03
CN101589025B (zh)	2012-05-30
NO341991B1 (no)	2018-03-12
US20120294854A1 (en)	2012-11-22
BRPI0717697B1 (pt)	2022-05-03
MY153393A (en)	2015-02-13
RS52514B (sr)	2013-04-30
ME01475B (me)	2014-04-20
PE20081846A1 (es)	2008-12-27
NZ577017A (en)	2011-12-22
JP2010513362A (ja)	2010-04-30
AR064444A1 (es)	2009-04-01
CA2674512C (en)	2015-09-08
AU2007338321B2 (en)	2012-01-19
PT2121614E (pt)	2012-08-31
CY1113687T1 (el)	2016-06-22

Publication	Publication Date	Title
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0918194A2 (pt)	2015-12-01	''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI1005153A2 (pt)	2019-09-24	composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0816814A2 (pt)	2017-05-16	composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.

Legal Events

Date	Code	Title	Description
2016-08-09	B25D	Requested change of name of applicant approved	Owner name: ALMIRALL, S.A. (ES)
2019-01-29	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-02	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-07-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-09-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-09-08	B15K	Others concerning applications: alteration of classification	Free format text: AS CLASSIFICACOES ANTERIORES ERAM: H01L 21/04 , H01L 29/24 , H01L 29/872 Ipc: C07D 213/79 (2006.01), C07D 213/80 (2006.01), A61K
2021-11-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-03-08	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-05-03	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.